作者
D Miles, J Gligorov, F André, D Cameron, A Schneeweiss, C Barrios, B Xu, A Wardley, D Kaen, L Andrade, V Semiglazov, M Reinisch, S Patel, M Patre, L Morales, SL Patel, M Kaul, T Barata, J O’shaughnessy, Q Zhang, Z Shao, X Wang, C Geng, X Yan, Z Tong, K Shen, Y Yin, T Sun, J Yang, J Feng, M Yan, Y Wang, Q Liu, S Zhang, M De Laurentiis, A Santoro, V Guarneri, M Colleoni, C Natoli, L Cortesi, S Placido, L Gianni, F Ferrau, L Livi, A Zambelli, L Del Mastro, G Tonini, F Montemurro, G Bianchi, R Pedersini, S Prete, G Allegrini, G Naso, P Vici, D Loirat, A Mailliez, F Priou, O Tredan, F Dalenc, C Perrin, M Timar David, N Dohollou, L Teixeira, F Brocard, A Arnaud, S Delaloge, J-P Spano, L Mansi, F Damian, J Pedrini, S Aleixo, R Hegg, R Junior, M Schmidt, C Wenzel, E-M Grischke, M Just, N Harbeck, C Schumacher, U Peters, D Fischer, H Forstbauer, R Liersch, E Warner, N Bouganim, C Doyle, J Price Hiller, T Vandenberg, M Pavic, A Robinson, G Roldan Urgoiti, N Califaretti, A Alacacioglu, M Gumus, B Yalcin, I Cicin, F Kose, K Uygun, M Kaplan, E Cubukcu, M Harries, D Doval, S Gupta, P Mohapatra, S Chatterjee, N Ghadyalpatil, M Singhal, S Nag, A Agarwal, I Wolf, E Gal Yam, R Yerushalmi, T Peretz, G Fried, N Ben Baruch, D Katz, E Hamilton, F Kayali, A Brufsky, M Telli, G Wright, R Oyola, T Rakowski, S Graff, S Tjulandin, A Aparicio, M Ruiz Borrego, L Merino, J Guerra Martinez, E Lopez, T Yamashita, S Ohtani, K Inoue, Y Ito, N Niikura, T Nakayama, Y Sagara, Y Yanagita, Y Kamada, K Kaneko, A Nervo, A Eniu, M Schenker, P Priester, B Melichar, M Zimovjanova, P Sormova, J Sufliarsky, M Kakalejcik, R Belbaraka
发表日期
2021/8/1
期刊
Annals of Oncology
卷号
32
期号
8
页码范围
994-1004
出版商
Elsevier
简介
Background
In the phase III IMpassion130 trial, combining atezolizumab with first-line nanoparticle albumin-bound-paclitaxel for advanced triple-negative breast cancer (aTNBC) showed a statistically significant progression-free survival (PFS) benefit in the intention-to-treat (ITT) and programmed death-ligand 1 (PD-L1)-positive populations, and a clinically meaningful overall survival (OS) effect in PD-L1-positive aTNBC. The phase III KEYNOTE-355 trial adding pembrolizumab to chemotherapy for aTNBC showed similar PFS effects. IMpassion131 evaluated first-line atezolizumab–paclitaxel in aTNBC.
Patients and methods
Eligible patients [no prior systemic therapy or ≥12 months since (neo)adjuvant chemotherapy] were randomised 2:1 to atezolizumab 840 mg or placebo (days 1, 15), both with paclitaxel 90 mg/m2 (days 1, 8, 15), every 28 days until disease progression or unacceptable toxicity. Stratification factors …
学术搜索中的文章
D Miles, J Gligorov, F André, D Cameron… - Annals of Oncology, 2021